Heart failure & cardiomyopathies
Relationship between sex, body size, and cardiac resynchronization therapy benefit: A patient-level meta-analysis of randomized controlled trials
Authors' conclusion
Although body size partially explains sex-specific QRS duration thresholds for CRT benefit, it is not associated with the magnitude of CRT benefit.
Study context
- Population
- Patients in cardiac resynchronization therapy (CRT) trials (MIRACLE, MIRACLE ICD, MIRACLE ICD II, REVERSE, RAFT, COMPANION, MADIT-CRT)patient-level data, CRT trials
- Participants
- 1,439 vs 5,628
- Comparison
- CRT effect in women vs men
- Womenn = 1,439
- Menn = 5,628reference
- Outcome
- HF hospitalization (HFH) or death; all-cause mortality
Methodological detailsbayesian hierarchical Weibull regression, sex-stratified analyses
- Bayesian hierarchical Weibull regression
- Sex-stratified analyses
Pooled result
As reported in the abstract
HFH or death, CRT effect by sex (adjusted)
Hazard ratio (CrI)
Womenvs MenCrI; CRT effect in women
0.54(0.42–0.70)
MenCrI; CRT effect in men
0.77(0.66–0.89)
Further pooled results
Height
P < 0.001
BSA
P < 0.001
QRS duration at which CRT effect on HFH or death observed
QRS duration at which CRT effect on heart failure hospitalization (HFH) or death observed
- Indexing QRS duration by height, body surface area (BSA) or left ventricular end-diastolic dimension (LVEDD) attenuated sex-specific QRS thresholds for HFH or death but not mortality
Sex-specific differences by cardiomyopathy type (subgroup)
- Sex-specific differences observed only in nonischemic cardiomyopathy
Original publication
Relationship between sex, body size, and cardiac resynchronization therapy benefit: A patient-level meta-analysis of randomized controlled trials. Heart Rhythm. Published 14 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →